中恒集团：控股子公司及控股孙公司部分产品拟中选国家集采药品接续采购

Core Viewpoint - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd. (referred to as "Laimei Pharmaceutical"), and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd. (referred to as "Hunan Kangyuan"), participated in the national centralized procurement for drugs whose agreements have expired, indicating potential selection for procurement which could enhance sales and market expansion [1] Group 1 - Laimei Pharmaceutical and Hunan Kangyuan participated in the bidding organized by the National Centralized Procurement Office for drugs with expired agreements [1] - The procurement is led by a coalition of provinces and regions, including Jiangsu, Henan, and Guangdong, focusing on products from the first eight batches of the national centralized procurement [1] - If procurement agreements are signed and implemented, it will positively impact the sales and brand influence of the selected products, contributing to the long-term development of the company [1]